> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track for Merrimack Lung Cancer Drug
- URL: https://www.fdaweb.com/fast-track-for-merrimack-lung-cancer-drug/
- Published: 2016-07-12T12:00:00.000Z
- Updated: 2026-09-14T21:13:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136156

FDA has granted Merrimack Pharmaceuticals fast track status for MM-121 (seribantumab) for treating patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following immunotherapy. Currently, Merrimack is conducting the SHERLOC trial, a global clinical study of seribantumab in combination with docetaxel or pemetrexed in heregulin-positive patients with NSCLC that is designed to support a future BLA submission. The company says the human monoclonal antibody was designed to target ErbB3 and phenotypically distinct heregulin-positive cancer cells within solid tumors. “Heregulin-positive cancer cells are characterized by their ability to escape the effects of targeted, cytotoxic and anti-endocrine therapies and potentially contribute to rapid clinical progression in patients whose tumor cells test positive for heregulin as detected by RNA-ISH,” it says.